Vuxen Group (VUXEN) Q4 23/24 earnings summary

Executive summary

• Achieved record annual revenue of 204.4 MSEK, up 4.7% year-over-year, with EBITDA rising 36.5% to 16.8 MSEK for 23/24.

• Q4 sales declined 1.5% to 43.7 MSEK compared to the same quarter last year, but gross margin improved to 48.8% from 45.7%.

• Growth driven by international expansion and increased share of own brands, offsetting weaker Swedish market.

• Maintained profitability and strong financial position despite challenging macroeconomic conditions.

Financial highlights

• Full-year revenue: 204.4 MSEK (up 4.7% year-over-year); Q4 revenue: 43.7 MSEK (down 1.5%).

• Full-year EBITDA: 16.8 MSEK (up from 12.3 MSEK); Q4 EBITDA: 3.1 MSEK (down from 4.3 MSEK).

• Full-year EBITDA margin: 8.2% (up from 6.3%); Q4 EBITDA margin: 7.0% (down from 9.6%).

• Full-year EBIT: 9.4 MSEK; Q4 EBIT: 1.2 MSEK.

• Full-year net income: 8.2 MSEK; Q4 net income: 0.9 MSEK.

Outlook and guidance

• Plans to expand sexual health offering to more European countries and continue international growth.

• Business built for scalability, enabling expansion without major new investments.

• Focus remains on organic growth, own brands, and selective acquisitions.